Reports & Presentations
Subsidiary Financials 2018 -19
- Glenmark Life Sciences Limited
- Glenmark Biotherapeutics SA
- Glenmark Brazil
- Glenmark Dominicana SRl
- Glenmark Germany
- Glenmark Holding SA
- Glenmark Pharmaceuticals ( Malaysia) Sdn Bhd
- Glenmark Pharmaceuticals (Australia) Pty Ltd
- Glenmark Pharmaceuticals (Kenya) Ltd
- Glenmark Pharmaceuticals (Thailand) Company Ltd
- Glenmark Pharmaceuticals BV
- Glenmark Pharmaceuticals Canada GPCI
- Glenmark Pharmaceuticals Colombia Sas
- Glenmark Pharmaceuticals Ecuador S A
- Glenmark Pharmaceuticals Egypt Company SAE
- Glenmark Pharmaceuticals Europe Ltd. GPEL
- Glenmark Pharmaceuticals Europe Ltd
- Glenmark Pharmaceuticals Fze UAE
- Glenmark Pharmaceuticals Inc.
- Glenmark Pharmaceuticals Mexico S A De C V
- Glenmark Pharmaceuticals Nigeria Ltd
- Glenmark Pharmaceuticals Peru S A
- Glenmark Pharmaceuticals SA
- Glenmark Pharmaceuticals Singapore Pte Ltd
- Glenmark Pharmaceuticals SRL
- Glenmark Pharmaceuticals Venezuela C A
- Glenmark Phillppines Inc Phillippines
- Glenmark South Africa Proprietary Limited
- Glenmark Therapeutics Ag Switzerland
- Glenmark Ukraine LLC
- Glenmark Uruguay S A
- GP Distribution S.R.O Prague
- GP SP. Z.O.O
- GPL Europe R&D ltd
- GPL Nordic AB
- GPL S.R.O Praha
- GPL SK, S.R.O Bratislava
- Viso Farmaceutica S.L.U, SPAIN
